FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and relates to a stable composition for intrathecal administration, containing an iduronate-2-sulfatase (I2S) protein at a concentration of 10 mg/ml to 150 mg/ml, wherein said composition contains NaCl in a concentration of 137-154 mM and not more than 50 mM phosphate. Group of inventions also relates to a method for treating a Hunters syndrome, comprising a step of intrathecal administration of said composition to a subject in need of treatment; use of said composition for the preparation of a medicament for the treatment of Hunters syndrome.
EFFECT: group of inventions provides an increase in the concentration of protein in the composition for intrathecal delivery as compared to known compositions.
46 cl, 64 dwg, 27 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR DELIVERY OF IDURONATE-2-SULPHATASE TO CNS | 2011 |
|
RU2774112C2 |
| MEDICAL AGENTS DELIVERY TO THE CENTRAL NERVOUS SYSTEM | 2011 |
|
RU2626514C2 |
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | 2011 |
|
RU2671503C2 |
| METHODS AND COMPOSITIONS FOR DELIVERY OF ARYLSULFATASE A TO CNS | 2011 |
|
RU2783380C2 |
| THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS | 2017 |
|
RU2751235C2 |
| VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2804953C2 |
| ADENO-ASSOCIATED VIRUS VECTOR FOR THERAPEUTIC DELIVERY INTO THE CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2751952C2 |
| TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOF | 2013 |
|
RU2680581C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| COMPOUND CONTAINING THERAPEUTIC ENZYME AND TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING LINKER | 2022 |
|
RU2811100C1 |
